Regorafenib suppresses sinusoidal obstruction syndrome in rats
نویسندگان
چکیده
منابع مشابه
Regorafenib suppresses sinusoidal obstruction syndrome in rats.
BACKGROUND Sinusoidal obstruction syndrome (SOS), a form of drug-induced liver injury related to oxaliplatin treatment, is associated with postoperative morbidity after hepatectomy. This study aimed to examine the impact of regorafenib, the first small-molecule kinase inhibitor to show efficacy against metastatic colorectal cancer, on a rat model of SOS. METHODS Rats with monocrotaline (MCT)-...
متن کاملTusanqi-Related Sinusoidal Obstruction Syndrome in China
(1) Duplicates amon (2) Duplicate public journals; Editor: Giovanni Tarantino. Received: April 5, 2015; revised: May 4, 2015; accepted: May 6, 2015. From the Department of Gastroenterology, General, Hospital of Shenyang Military Area (XW, XQ, XG); and Postgraduate College, Liaoning University of Traditional Chinese Medicine (XW), Shenyang, China. Correspondence: Prof Xiaozhong Guo, MD, PhD, and...
متن کاملSinusoidal obstruction syndrome after oxaliplatin-based chemotherapy
Drug-induced liver injury presents with extremely diverse histologic patterns, including necroinflammatory, cholestatic, steatotic and vascular patterns. Sinusoidal obstruction syndrome (SOS), also referred to as toxic sinusoidal injury, veno-occlusive disease or “blue liver syndrome”, is a commonly recognized vascular pattern of drug-induced liver injury, and has been frequently associated wit...
متن کاملEmbolization by sinusoidal lining cells obstructs the microcirculation in rat sinusoidal obstruction syndrome.
Mechanisms leading to the obstruction of the microcirculation in sinusoidal obstruction syndrome (SOS) have been unclear. Because this occurs at the onset of disease, this is a potential key target for therapeutic intervention. Rats were treated with monocrotaline with or without continuous intraportal infusion of glutathione and were studied at 0.5, 1, 2, 4, 6, and 10 days after monocrotaline ...
متن کاملHepatic sinusoidal obstruction syndrome following hematopoietic stem cell transplantation.
J.m., a 43-year-old man with acute myelogenous leukemia with a monosomy 7 cytogenetic abnormality, received an allogeneic hematopoietic stem cell transplantation (HscT) from his human leukocyte antigen– matched brother. Past treatments included idarubicin and cytarabine induction therapy followed by a cycle of high-dose cytarabine. J.m. was in complete remission prior to the HscT. The condition...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Surgical Research
سال: 2015
ISSN: 0022-4804
DOI: 10.1016/j.jss.2014.08.052